Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Vassiliki A. Boussiotis, Ph.D., M.D.

TitleProfessor of Medicine
InstitutionBeth Israel Deaconess Medical Center
DepartmentMedicine
AddressBeth Israel Deaconess Medical Center
Nrb 1030h
330 Brookline Ave
Boston MA 02215
Phone617/632-4586

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Li L, Kim HT, Nellore A, Patsoukis N, Petkova V, McDonough S, Politikos I, Nikiforow S, Soiffer R, Antin JH, Ballen K, Cutler C, Ritz J, Boussiotis VA. Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/ß-catenin pathway and alters immune reconstitution after UCBT. Blood Cancer J. 2014; 4:e178.
    View in: PubMed
  2. Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA. PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2. Mol Cell Biol. 2013 Aug; 33(16):3091-8.
    View in: PubMed
  3. Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, Dey BR, Somaiya P, Mills H, Campigotto F, Weller E, Joyce R, Levine JD, Tzachanis D, Richardson P, Laubach J, Raje N, Boussiotis V, Yuan YE, Bisharat L, Held V, Rowe J, Anderson K, Kufe D, Avigan D. Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients. Clin Cancer Res. 2013 Jul 1; 19(13):3640-8.
    View in: PubMed
  4. Li L, Boussiotis VA. The role of IL-17-producing Foxp3(+) CD4(+) T cells in inflammatory bowel disease and colon cancer. Clin Immunol. 2013 Aug; 148(2):246-53.
    View in: PubMed
  5. Medraño-Fernandez I, Reyes R, Olazabal I, Rodriguez E, Sanchez-Madrid F, Boussiotis VA, Reche PA, Cabañas C, Lafuente EM. RIAM (Rap1-interacting adaptor molecule) regulates complement-dependent phagocytosis. Cell Mol Life Sci. 2013 Jul; 70(13):2395-410.
    View in: PubMed
  6. Wynne JP, Wu J, Su W, Mor A, Patsoukis N, Boussiotis VA, Hubbard SR, Philips MR. Rap1-interacting adapter molecule (RIAM) associates with the plasma membrane via a proximity detector. J Cell Biol. 2012 Oct 15; 199(2):317-29.
    View in: PubMed
  7. Patsoukis N, Sari D, Boussiotis VA. PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle. 2012 Dec 1; 11(23):4305-9.
    View in: PubMed
  8. Li L, Patsoukis N, Petkova V, Boussiotis VA. Runx1 and Runx3 are involved in the generation and function of highly suppressive IL-17-producing T regulatory cells. PLoS One. 2012; 7(9):e45115.
    View in: PubMed
  9. Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal. 2012 Jun 26; 5(230):ra46.
    View in: PubMed
  10. Li L, Boussiotis VA. Molecular and functional heterogeneity of T regulatory cells. Clin Immunol. 2011 Dec; 141(3):244-52.
    View in: PubMed
  11. Hernández-Varas P, Coló GP, Bartolomé RA, Paterson A, Medraño-Fernández I, Arellano-Sánchez N, Cabañas C, Sánchez-Mateos P, Lafuente EM, Boussiotis VA, Strömblad S, Teixidó J. Rap1-GTP-interacting adaptor molecule (RIAM) protein controls invasion and growth of melanoma cells. J Biol Chem. 2011 May 27; 286(21):18492-504.
    View in: PubMed
  12. Li L, Kim Js, Boussiotis VA. Rap1A regulates generation of T regulatory cells via LFA-1-dependent and LFA-1-independent mechanisms. Cell Immunol. 2010; 266(1):7-13.
    View in: PubMed
  13. Li L, Kim J, Boussiotis VA. IL-1ß-mediated signals preferentially drive conversion of regulatory T cells but not conventional T cells into IL-17-producing cells. J Immunol. 2010 Oct 1; 185(7):4148-53.
    View in: PubMed
  14. Cutler C, Stevenson K, Kim HT, Brown J, McDonough S, Herrera M, Reynolds C, Liney D, Kao G, Ho V, Armand P, Koreth J, Alyea E, Dey BR, Attar E, Spitzer T, Boussiotis VA, Ritz J, Soiffer R, Antin JH, Ballen K. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant. 2011 May; 46(5):659-67.
    View in: PubMed
  15. Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, Friedman T, Konstantinopoulos PA, Spentzos D, Ghebremichael M, Stevenson K, Neuberg D, Levine JD, Joyce R, Tzachanis D, Boussiotis V, Kufe D, Avigan D. Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother. 2010 Feb-Mar; 33(2):155-66.
    View in: PubMed
  16. Brown JA, Stevenson K, Kim HT, Cutler C, Ballen K, McDonough S, Reynolds C, Herrera M, Liney D, Ho V, Kao G, Armand P, Koreth J, Alyea E, McAfee S, Attar E, Dey B, Spitzer T, Soiffer R, Ritz J, Antin JH, Boussiotis VA. Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood. 2010 May 20; 115(20):4111-9.
    View in: PubMed
  17. Rosenblatt J, Bissonnette A, Ahmad R, Wu Z, Vasir B, Stevenson K, Zarwan C, Keefe W, Glotzbecker B, Mills H, Joyce R, Levine JD, Tzachanis D, Boussiotis V, Kufe D, Avigan D. Immunomodulatory effects of vitamin D: implications for GVHD. Bone Marrow Transplant. 2010 Sep; 45(9):1463-8.
    View in: PubMed
  18. Patsoukis N, Lafuente EM, Meraner P, Kim Js, Dombkowski D, Li L, Boussiotis VA. RIAM regulates the cytoskeletal distribution and activation of PLC-gamma1 in T cells. Sci Signal. 2009; 2(99):ra79.
    View in: PubMed
  19. Li L, Wang H, Kim Js, Pihan G, Boussiotis V. The cyclin dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD. Cell Cycle. 2009 Jun 1; 8(11):1794 - 1802.
    View in: PubMed
  20. Tzachanis D, Boussiotis VA. Tob, a member of the APRO family, regulates immunological quiescence and tumor suppression. Cell Cycle. 2009 Apr 1; 8(7):1019-25.
    View in: PubMed
  21. Zhou D, Medoff BD, Chen L, Li L, Zhang XF, Praskova M, Liu M, Landry A, Blumberg RS, Boussiotis VA, Xavier R, Avruch J. The Nore1B/Mst1 complex restrains antigen receptor-induced proliferation of naïve T cells. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20321-6.
    View in: PubMed
  22. Cardoso BA, Martins LR, Santos CI, Nadler LM, Boussiotis VA, Cardoso AA, Barata JT. Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling. Leukemia. 2009 Jan; 23(1):206-8.
    View in: PubMed
  23. Watanabe N, Bodin L, Pandey M, Krause M, Coughlin S, Boussiotis VA, Ginsberg MH, Shattil SJ. Mechanisms and consequences of agonist-induced talin recruitment to platelet integrin alphaIIbbeta3. J Cell Biol. 2008 Jun 30; 181(7):1211-22.
    View in: PubMed
  24. Ge X, Brown J, Sykes M, Boussiotis VA. CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors. Biol Blood Marrow Transplant. 2008 May; 14(5):518-30.
    View in: PubMed
  25. Friedberg J, Jacobsen E, Neuberg D, Kutok J, Munoz O, Boussiotis V, Reynolds H, Fisher D, Szot A, Van Den Abbeele A, Freedman A. Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. Leuk Lymphoma. 2008 May; 49(5):902-9.
    View in: PubMed
  26. Brown JA, Boussiotis VA. Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution. Clin Immunol. 2008 Jun; 127(3):286-97.
    View in: PubMed
  27. Muzio M, Apollonio B, Scielzo C, Frenquelli M, Vandoni I, Boussiotis V, Caligaris-Cappio F, Ghia P. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood. 2008 Jul 1; 112(1):188-95.
    View in: PubMed
  28. Li L, Boussiotis VA. Control and regulation of peripheral tolerance in allergic inflammatory disease: therapeutic consequences. Chem Immunol Allergy. 2008; 94:178-88.
    View in: PubMed
  29. O'Shaughnessy MJ, Chen ZM, Gramaglia I, Taylor PA, Panoskaltsis-Mortari A, Vogtenhuber C, Palmer E, Grader-Beck T, Boussiotis VA, Blazar BR. Elevation of intracellular cyclic AMP in alloreactive CD4(+) T Cells induces alloantigen-specific tolerance that can prevent GVHD lethality in vivo. Biol Blood Marrow Transplant. 2007 May; 13(5):530-42.
    View in: PubMed
  30. Lafuente EM, Iwamoto Y, Carman CV, van Puijenbroek AA, Constantine E, Li L, Boussiotis VA. Active Rap1, a small GTPase that induces malignant transformation of hematopoietic progenitors, localizes in the nucleus and regulates protein expression. Leuk Lymphoma. 2007 May; 48(5):987-1002.
    View in: PubMed
  31. Tzachanis D, Li L, Lafuente EM, Berezovskaya A, Freeman GJ, Boussiotis VA. Twisted gastrulation (Tsg) is regulated by Tob and enhances TGF-beta signaling in activated T lymphocytes. Blood. 2007 Apr 1; 109(7):2944-52.
    View in: PubMed
  32. Li L, Iwamoto Y, Berezovskaya A, Boussiotis VA. A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance. Nat Immunol. 2006 Nov; 7(11):1157-65.
    View in: PubMed
  33. Han J, Lim CJ, Watanabe N, Soriani A, Ratnikov B, Calderwood DA, Puzon-McLaughlin W, Lafuente EM, Boussiotis VA, Shattil SJ, Ginsberg MH. Reconstructing and deconstructing agonist-induced activation of integrin alphaIIbbeta3. Curr Biol. 2006 Sep 19; 16(18):1796-806.
    View in: PubMed
  34. Appleman LJ, Chernova I, Li L, Boussiotis VA. CD28 costimulation mediates transcription of SKP2 and CKS1, the substrate recognition components of SCFSkp2 ubiquitin ligase that leads p27kip1 to degradation. Cell Cycle. 2006 Sep; 5(18):2123-9.
    View in: PubMed
  35. Li L, Boussiotis VA. Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications. J Mol Med (Berl). 2006 Nov; 84(11):887-99.
    View in: PubMed
  36. Lafuente E, Boussiotis VA. Rap1 regulation of RIAM and cell adhesion. Methods Enzymol. 2006; 407:345-58.
    View in: PubMed
  37. Li L, Greenwald RJ, Lafuente EM, Tzachanis D, Berezovskaya A, Freeman GJ, Sharpe AH, Boussiotis VA. Rap1-GTP is a negative regulator of Th cell function and promotes the generation of CD4+CD103+ regulatory T cells in vivo. J Immunol. 2005 Sep 1; 175(5):3133-9.
    View in: PubMed
  38. Li L, Godfrey WR, Porter SB, Ge Y, June CH, Blazar BR, Boussiotis VA. CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood. 2005 Nov 1; 106(9):3068-73.
    View in: PubMed
  39. Barata JT, Cardoso AA, Boussiotis VA. Interleukin-7 in T-cell acute lymphoblastic leukemia: an extrinsic factor supporting leukemogenesis? Leuk Lymphoma. 2005 Apr; 46(4):483-95.
    View in: PubMed
  40. Appleman LJ, Boussiotis V. In vitro models of human T cell anergy. Curr Protoc Immunol. 2005 Mar; Chapter 7:Unit 7.36.
    View in: PubMed
  41. Barata JT, Keenan TD, Silva A, Nadler LM, Boussiotis VA, Cardoso AA. Common gamma chain-signaling cytokines promote proliferation of T-cell acute lymphoblastic leukemia. Haematologica. 2004 Dec; 89(12):1459-67.
    View in: PubMed
  42. Vassilakopoulos TP, Angelopoulou MK, Constantinou N, Karmiris T, Repoussis P, Roussou P, Siakantaris MP, Korkolopoulou P, Kyrtsonis MC, Kokoris SI, Dimopoulou MN, Variamis E, Viniou NA, Konstantopoulos K, Dimitriadou EM, Androulaki A, Patsouris E, Doussis-Anagnostopoulou IA, Panayiotidis P, Boussiotis VA, Kittas C, Pangalis GA. Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma. Blood. 2005 Mar 1; 105(5):1875-80.
    View in: PubMed
  43. Tzachanis D, Lafuente EM, Li L, Boussiotis VA. Intrinsic and extrinsic regulation of T lymphocyte quiescence. Leuk Lymphoma. 2004 Oct; 45(10):1959-67.
    View in: PubMed
  44. Krause M, Leslie JD, Stewart M, Lafuente EM, Valderrama F, Jagannathan R, Strasser GA, Rubinson DA, Liu H, Way M, Yaffe MB, Boussiotis VA, Gertler FB. Lamellipodin, an Ena/VASP ligand, is implicated in the regulation of lamellipodial dynamics. Dev Cell. 2004 Oct; 7(4):571-83.
    View in: PubMed
  45. Lafuente EM, van Puijenbroek AA, Krause M, Carman CV, Freeman GJ, Berezovskaya A, Constantine E, Springer TA, Gertler FB, Boussiotis VA. RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-GTP and mediates Rap1-induced adhesion. Dev Cell. 2004 Oct; 7(4):585-95.
    View in: PubMed
  46. Barata JT, Silva A, Brandao JG, Nadler LM, Cardoso AA, Boussiotis VA. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med. 2004 Sep 6; 200(5):659-69.
    View in: PubMed
  47. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Karkantaris C, Anargyrou K, Boutsis DE, Variamis E, Michalopoulos T, Boussiotis VA, Panayiotidis P, Papavassiliou C, Pangalis GA. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2004 Jul 1; 59(3):765-81.
    View in: PubMed
  48. Barata JT, Boussiotis VA, Yunes JA, Ferrando AA, Moreau LA, Veiga JP, Sallan SE, Look AT, Nadler LM, Cardoso AA. IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL. Blood. 2004 Mar 1; 103(5):1891-900.
    View in: PubMed
  49. Tzachanis D, Appleman LJ, Van Puijenbroek AA, Berezovskaya A, Nadler LM, Boussiotis VA. Differential localization and function of ADP-ribosylation factor-6 in anergic human T cells: a potential marker for their identification. J Immunol. 2003 Aug 15; 171(4):1691-6.
    View in: PubMed
  50. Appleman LJ, Boussiotis VA. T cell anergy and costimulation. Immunol Rev. 2003 Apr; 192:161-80.
    View in: PubMed
  51. Grader-Beck T, van Puijenbroek AA, Nadler LM, Boussiotis VA. cAMP inhibits both Ras and Rap1 activation in primary human T lymphocytes, but only Ras inhibition correlates with blockade of cell cycle progression. Blood. 2003 Feb 1; 101(3):998-1006.
    View in: PubMed
  52. Appleman LJ, Tzachanis D, Grader-Beck T, Van Puijenbroek AA, Boussiotis VA. Induction of immunologic tolerance for allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2002 Jun; 43(6):1159-67.
    View in: PubMed
  53. Delgado JC, Tsai EY, Thim S, Baena A, Boussiotis VA, Reynes JM, Sath S, Grosjean P, Yunis EJ, Goldfeld AE. Antigen-specific and persistent tuberculin anergy in a cohort of pulmonary tuberculosis patients from rural Cambodia. Proc Natl Acad Sci U S A. 2002 May 28; 99(11):7576-81.
    View in: PubMed
  54. Appleman LJ, van Puijenbroek AA, Shu KM, Nadler LM, Boussiotis VA. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J Immunol. 2002 Mar 15; 168(6):2729-36.
    View in: PubMed
  55. Tzachanis D, Berezovskaya A, Nadler LM, Boussiotis VA. Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T-cell responses. Blood. 2002 Feb 15; 99(4):1465-73.
    View in: PubMed
  56. Greenwald RJ, Oosterwegel MA, van der Woude D, Kubal A, Mandelbrot DA, Boussiotis VA, Sharpe AH. CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol. 2002 Feb; 32(2):366-73.
    View in: PubMed
  57. Tzachanis D, Freeman GJ, Hirano N, van Puijenbroek AA, Delfs MW, Berezovskaya A, Nadler LM, Boussiotis VA. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol. 2001 Dec; 2(12):1174-82.
    View in: PubMed
  58. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Barbounis A, Grigorakis V, Karkantaris C, Anargyrou K, Chatziioannou M, Rombos J, Boussiotis VA, Vaiopoulos G, Kittas C, Pangalis GA. Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites. Eur J Haematol. 2001 Nov-Dec; 67(5-6):279-88.
    View in: PubMed
  59. Kyrtsonis MC, Vassilakopoulos TP, Angelopoulou MK, Siakantaris P, Kontopidou FN, Dimopoulou MN, Boussiotis V, Gribabis A, Konstantopoulos K, Vaiopoulos GA, Fessas P, Kittas C, Pangalis GA. Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit. Ann Hematol. 2001 Dec; 80(12):722-7.
    View in: PubMed
  60. Barata JT, Cardoso AA, Nadler LM, Boussiotis VA. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood. 2001 Sep 1; 98(5):1524-31.
    View in: PubMed
  61. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001 Mar; 2(3):261-8.
    View in: PubMed
  62. Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, Sharpe AH. CTLA-4 regulates induction of anergy in vivo. Immunity. 2001 Feb; 14(2):145-55.
    View in: PubMed
  63. Boussiotis VA, Chen ZM, Zeller JC, Murphy WJ, Berezovskaya A, Narula S, Roncarolo MG, Blazar BR. Altered T-cell receptor + CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-beta-treated alloreactive T cells that do not induce graft-versus-host disease. Blood. 2001 Jan 15; 97(2):565-71.
    View in: PubMed
  64. Appleman LJ, Tzachanis D, Grader-Beck T, van Puijenbroek AA, Boussiotis VA. Helper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics. J Mol Med (Berl). 2001; 78(12):673-83.
    View in: PubMed
  65. McAdam AJ, Chang TT, Lumelsky AE, Greenfield EA, Boussiotis VA, Duke-Cohan JS, Chernova T, Malenkovich N, Jabs C, Kuchroo VK, Ling V, Collins M, Sharpe AH, Freeman GJ. Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J Immunol. 2000 Nov 1; 165(9):5035-40.
    View in: PubMed
  66. Boussiotis VA, Tsai EY, Yunis EJ, Thim S, Delgado JC, Dascher CC, Berezovskaya A, Rousset D, Reynes JM, Goldfeld AE. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest. 2000 May; 105(9):1317-25.
    View in: PubMed
  67. Boussiotis VA, Freeman GJ, Taylor PA, Berezovskaya A, Grass I, Blazar BR, Nadler LM. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med. 2000 Mar; 6(3):290-7.
    View in: PubMed
  68. Angelopoulou MK, Vassilakopoulos TP, Siakantaris MP, Kontopidou FN, Boussiotis VA, Papavassiliou C, Kittas C, Pangalis GA. EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease. Leuk Lymphoma. 2000 Mar; 37(1-2):131-43.
    View in: PubMed
  69. Appleman LJ, Berezovskaya A, Grass I, Boussiotis VA. CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J Immunol. 2000 Jan 1; 164(1):144-51.
    View in: PubMed
  70. Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, Gribben JG. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999 Jun 3; 340(22):1704-14.
    View in: PubMed
  71. Boussiotis VA, Freedman AS, Nadler LM. Bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Semin Hematol. 1999 Apr; 36(2):209-16.
    View in: PubMed
  72. Boussiotis VA, Freeman GJ, Gribben JG, Hayes DF, Nadler LM. No evidence for MUC 1-induced apoptosis. Nat Med. 1998 Oct; 4(10):1093.
    View in: PubMed
  73. Freeman GJ, Cardoso AA, Boussiotis VA, Anumanthan A, Groves RW, Kupper TS, Clark EA, Nadler LM. The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor. J Immunol. 1998 Sep 15; 161(6):2708-15.
    View in: PubMed
  74. Ghia P, Boussiotis VA, Schultze JL, Cardoso AA, Dorfman DM, Gribben JG, Freedman AS, Nadler LM. Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood. 1998 Jan 1; 91(1):244-51.
    View in: PubMed
  75. Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM. Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science. 1997 Oct 3; 278(5335):124-8.
    View in: PubMed
  76. Boussiotis VA, Lee BJ, Freeman GJ, Gribben JG, Nadler LM. Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death. J Immunol. 1997 Oct 1; 159(7):3156-67.
    View in: PubMed
  77. Cardoso AA, Seamon MJ, Afonso HM, Ghia P, Boussiotis VA, Freeman GJ, Gribben JG, Sallan SE, Nadler LM. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood. 1997 Jul 15; 90(2):549-61.
    View in: PubMed
  78. Gimmi CD, Morrison BW, Mainprice BA, Gribben JG, Boussiotis VA, Freeman GJ, Park SY, Watanabe M, Gong J, Hayes DF, Kufe DW, Nadler LM. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med. 1996 Dec; 2(12):1367-70.
    View in: PubMed
  79. Hall KT, Boumsell L, Schultze JL, Boussiotis VA, Dorfman DM, Cardoso AA, Bensussan A, Nadler LM, Freeman GJ. Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11780-5.
    View in: PubMed
  80. Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM. The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol Rev. 1996 Oct; 153:5-26.
    View in: PubMed
  81. Boussiotis VA, Pardo NA, Collins H, Houghton A, Ritz J, Nadler LM, Soiffer RJ. R24 anti-GD3 ganglioside antibody can induce costimulation and prevent the induction of alloantigen-specific T cell clonal anergy. Eur J Immunol. 1996 Sep; 26(9):2149-54.
    View in: PubMed
  82. Boussiotis VA, Barber DL, Lee BJ, Gribben JG, Freeman GJ, Nadler LM. Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. J Exp Med. 1996 Aug 1; 184(2):365-76.
    View in: PubMed
  83. Cardoso AA, Schultze JL, Boussiotis VA, Freeman GJ, Seamon MJ, Laszlo S, Billet A, Sallan SE, Gribben JG, Nadler LM. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood. 1996 Jul 1; 88(1):41-8.
    View in: PubMed
  84. Gribben JG, Guinan EC, Boussiotis VA, Ke XY, Linsley L, Sieff C, Gray GS, Freeman GJ, Nadler LM. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood. 1996 Jun 1; 87(11):4887-93.
    View in: PubMed
  85. Angelopoulou MA, Poziopoulos C, Boussiotis VA, Kontopidou F, Pangalis GA. Fludarabine monophosphate in refractory B-chronic lymphocytic leukemia: maintenance may be significant to sustain response. Leuk Lymphoma. 1996 Apr; 21(3-4):321-4.
    View in: PubMed
  86. Souliotis VL, Valavanis C, Boussiotis VA, Pangalis GA, Kyrtopoulos SA. Comparative study of the formation and repair of O6-methylguanine in humans and rodents treated with dacarbazine. Carcinogenesis. 1996 Apr; 17(4):725-32.
    View in: PubMed
  87. Freeman GJ, Boussiotis VA, Anumanthan A, Bernstein GM, Ke XY, Rennert PD, Gray GS, Gribben JG, Nadler LM. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity. 1995 May; 2(5):523-32.
    View in: PubMed
  88. Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM. The critical role of CD28 signalling in the prevention of human T-cell anergy. Res Immunol. 1995 Mar-Apr; 146(3):140-9.
    View in: PubMed
  89. Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL, Greenfield E, Barber M, Restivo VA, Ke X, Gray GS, et al. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci U S A. 1995 Jan 31; 92(3):811-5.
    View in: PubMed
  90. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood. 1994 Nov 15; 84(10):3261-82.
    View in: PubMed
  91. Boussiotis VA, Barber DL, Nakarai T, Freeman GJ, Gribben JG, Bernstein GM, D'Andrea AD, Ritz J, Nadler LM. Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science. 1994 Nov 11; 266(5187):1039-42.
    View in: PubMed
  92. Boussiotis VA, Freeman GJ, Griffin JD, Gray GS, Gribben JG, Nadler LM. CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy. J Exp Med. 1994 Nov 1; 180(5):1665-73.
    View in: PubMed
  93. Boussiotis VA, Gribben JG, Freeman GJ, Nadler LM. Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance. Curr Opin Immunol. 1994 Oct; 6(5):797-807.
    View in: PubMed
  94. Souliotis VL, Valavanis C, Boussiotis VA, Pangalis GA, Kyrtopoulos SA. Comparative dosimetry of O6-methylguanine in humans and rodents treated with procarbazine. Carcinogenesis. 1994 Aug; 15(8):1675-80.
    View in: PubMed
  95. Kourtis AP, Boussiotis VA, Lymberi P, Pangalis GA. Increased natural antibody activity in sera of patients with malignant non-Hodgkin's lymphomas containing paraproteins. Am J Hematol. 1994 Aug; 46(4):283-8.
    View in: PubMed
  96. Boussiotis VA, Nadler LM, Strominger JL, Goldfeld AE. Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells. Proc Natl Acad Sci U S A. 1994 Jul 19; 91(15):7007-11.
    View in: PubMed
  97. Korkolopoulou P, Pangalis GA, Patsouris E, Boussiotis VA, Kittas C. B-cell lymphoma of large multilobated type: an immunohistochemical study of 8 cases and review of the literature. Leuk Lymphoma. 1994 Mar; 13(1-2):151-9.
    View in: PubMed
  98. Gribabis DA, Panayiotidis P, Boussiotis VA, Hannoun C, Pangalis GA. Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients. Acta Haematol. 1994; 91(3):115-8.
    View in: PubMed
  99. Salles G, Zain M, Jiang WM, Boussiotis VA, Shipp MA. Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. Blood. 1993 Dec 15; 82(12):3539-47.
    View in: PubMed
  100. Pangalis GA, Vassilakopoulos TP, Boussiotis VA, Fessas P. Clinical approach to lymphadenopathy. Semin Oncol. 1993 Dec; 20(6):570-82.
    View in: PubMed
  101. Boussiotis VA, Freeman GJ, Gribben JG, Daley J, Gray G, Nadler LM. Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc Natl Acad Sci U S A. 1993 Dec 1; 90(23):11059-63.
    View in: PubMed
  102. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA, Lombard LA, Gray GS, Nadler LM. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science. 1993 Nov 5; 262(5135):909-11.
    View in: PubMed
  103. Boussiotis VA, Freeman GJ, Gray G, Gribben J, Nadler LM. B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med. 1993 Nov 1; 178(5):1753-63.
    View in: PubMed
  104. Pangalis GA, Boussiotis VA, Kittas C. Malignant disorders of small lymphocytes. Small lymphocytic lymphoma, lymphoplasmacytic lymphoma, and chronic lymphocytic leukemia: their clinical and laboratory relationship. Am J Clin Pathol. 1993 Apr; 99(4):402-8.
    View in: PubMed
  105. Kyrtopoulos SA, Souliotis VL, Valavanis C, Boussiotis VA, Pangalis GA. Accumulation of O6-methylguanine in human DNA after therapeutic exposure to methylating agents and its relationship with biological effects. Environ Health Perspect. 1993 Mar; 99:143-7.
    View in: PubMed
  106. Goldfeld AE, Flemington EK, Boussiotis VA, Theodos CM, Titus RG, Strominger JL, Speck SH. Transcription of the tumor necrosis factor alpha gene is rapidly induced by anti-immunoglobulin and blocked by cyclosporin A and FK506 in human B cells. Proc Natl Acad Sci U S A. 1992 Dec 15; 89(24):12198-201.
    View in: PubMed
  107. Boussiotis VA, Pangalis GA. Interferon alfa-2b therapy in untreated early stage, B-chronic lymphocytic leukaemia patients: one-year follow-up. Br J Haematol. 1991 Oct; 79 Suppl 1:30-3.
    View in: PubMed
  108. Pangalis GA, Boussiotis VA, Kittas C, Panayiotidis PG, Loukopoulos D, Fessas P, Mitsoulis-Mentzikoff C. Hairy cell leukemia: splenectomy after alpha 2b-interferon therapy. Blood. 1991 Sep 1; 78(5):1385.
    View in: PubMed
  109. Souliotis VL, Boussiotis VA, Pangalis GA, Kyrtopoulos SA. In vivo formation and repair of O6-methylguanine in human leukocyte DNA after intravenous exposure to dacarbazine. Carcinogenesis. 1991 Feb; 12(2):285-8.
    View in: PubMed
  110. Yataganas X, Meletis J, Plata E, Viniou N, Deligiannis F, Tsekoura C, Voscaridou E, Boussiotis V, Rombos J, Vayopoulos G, et al. alpha Interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis. Eur J Cancer. 1991; 27 Suppl 4:S69-71.
    View in: PubMed
  111. Boussiotis VA, Pangalis GA. Interferon alfa-2b in stage A untreated B-chronic lymphocytic leukaemia patients. Eur J Cancer. 1991; 27 Suppl 4:S78-9.
    View in: PubMed
  112. Souliotis VL, Kaila S, Boussiotis VA, Pangalis GA, Kyrtopoulos SA. Accumulation of O6-methylguanine in human blood leukocyte DNA during exposure to procarbazine and its relationships with dose and repair. Cancer Res. 1990 May 1; 50(9):2759-64.
    View in: PubMed
  113. Boussiotis VA, Pangalis GA. Randomized clinical trial with alpha 2b-interferon in 26 stage A untreated B-chronic lymphocytic leukemia patients. Nouv Rev Fr Hematol. 1988; 30(5-6):471-3.
    View in: PubMed
  114. Pangalis GA, Boussiotis VA, Kittas C. B-chronic lymphocytic leukemia. Disease progression in 150 untreated stage A and B patients as predicted by bone marrow pattern. Nouv Rev Fr Hematol. 1988; 30(5-6):373-5.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Boussiotis's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_